707 results on '"Ungaro, Ryan C."'
Search Results
2. Do We Need AI to Diagnose AI? Diagnosis and Management of Adrenal Insufficiency Following Steroid Therapy in a Patient with Inflammatory Bowel Disease
3. Electronic Health Records-based identification of newly diagnosed Crohn’s Disease cases
4. Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis
5. Per- and Poly-Fluoroalkyl Substances Exposure Is Associated With Later Occurrence of Inflammatory Bowel Disease
6. Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease
7. Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER)
8. Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry
9. Machine Learning Based Prediction of Incident Cases of Crohn’s Disease Using Electronic Health Records from a Large Integrated Health System
10. Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease
11. Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
12. Mild Crohn’s Disease: Definition and Management
13. Net Remission Rates with Biologic and Small Molecule Treatment in Ulcerative Colitis: A Reappraisal of the Clinical Trial Data
14. Preclinical Serological Signatures are Associated With Complicated Crohn’s Disease Phenotype at Diagnosis
15. Early Ileocecal Resection for Crohn’s Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study
16. Second–Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real–World Propensity Score–Weighted Analysis
17. Besting the Biologics: Vancomycin Monotherapy for Ulcerative Colitis Management in Patients with Primary Sclerosing Cholangitis
18. Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study
19. Net Remission Rates with Biologic Treatment in Crohn’s Disease: A Reappraisal of the Clinical Trial Data
20. Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis
21. Inflammatory Bowel Disease Is Associated With Prediagnostic Perturbances in Metabolic Pathways
22. Clinical Challenge: Proactive Precise Management of Active Ulcerative Colitis During Pregnancy—Advantages of Point-of-Care Intestinal Ultrasound and Therapeutic Drug Monitoring
23. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab
24. Feasibility and impact of a quality improvement initiative to screen for malnutrition in an Inflammatory Bowel Disease clinic
25. Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease
26. Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile
27. Is Prevention the Best Way to Modify Inflammatory Bowel Disease? How Close Are We?
28. Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant Disability
29. Review article: Prevention of inflammatory bowel disease—The path forward.
30. Molecular Characterization of Limited Ulcerative Colitis Reveals Novel Biology and Predictors of Disease Extension
31. Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience
32. COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States
33. Real-World Effectiveness and Safety of Tofacitinib in Crohn’s Disease and IBD-U: A Multicenter Study From the TROPIC Consortium
34. Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis
35. Recycling of Precolectomy Anti-Tumor Necrosis Factor Agents in Chronic Pouch Inflammation Is Associated With Treatment Failure
36. Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases
37. Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2–related Disease
38. Unmet needs in inflammatory bowel disease
39. Early Biologic Treatment Decreases Risk of Surgery in Crohn's Disease but not in Ulcerative Colitis: Systematic Review and Meta-Analysis.
40. Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus.
41. Toward Personalized Therapy in Inflammatory Bowel Disease
42. What Should Gastroenterologists and Patients Know About COVID-19?
43. Stopping Mesalamine Therapy in Patients With Crohn’s Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes
44. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID
45. Outcomes of COVID-19 Infections in Vaccinated Patients with Inflammatory Bowel Disease: Data From an International Registry
46. High Levels of Psychological Resilience Are Associated With Decreased Anxiety in Inflammatory Bowel Disease
47. Clinical long-term outcomes of patient-reported outcomes in the prospective real-world Tofacitinib Response in Ulcerative Colitis (TOUR) registry
48. Per- and poly-fluoroalkyl substances (PFAS) exposure is associated with later occurrence of inflammatory bowel disease
49. Improving Endoscopic Detection of Dysplasia in Inflammatory Bowel Disease: Where Do We Stand?
50. Early Biologic Initiation After Chronic Pouch Inflammation Diagnosis Does Not Impact Clinical Outcomes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.